Stocksigma LogoStocksigma Logo

Jagsonpal Pharmaceuticals Reports Q2FY27 Results and Inorganic Expansion

Jagsonpal Pharmaceuticals reported consolidated revenue growth of 29% YoY to ₹964 Mn in Q2FY27, while standalone revenue grew 9.3% YoY to ₹814 Mn with an

Jagsonpal Pharmaceuticals Reports Q2FY27 Results and Inorganic Expansion

Jagsonpal Pharmaceuticals Ltd · Press Release · 29 Oct 2026, 12:11 am

Jagsonpal Pharmaceuticals Reports Q2FY27 Results and Inorganic Expansion Jagsonpal Pharmaceuticals reported consolidated revenue growth of 29% YoY to ₹964 Mn in Q2FY27, while standalone revenue grew 9.3% YoY to ₹814 Mn with an EBITDA margin of 22.7% (₹185 Mn) and PAT of ₹126 Mn. In H1FY27, standalone revenue rose 9.0% YoY to ₹1,636 Mn and PAT rose 10.3% YoY to ₹258 Mn. Growth was aided by consolidating Aequitas Healthcare (acquired for ₹208 Mn cash) and completing the Group Pharma Wellness acquisition on 1st Oct'26, supporting the target to reach ₹5,000 Mn annual revenue by 2028.

Original exchange filing (PDF)

More announcements from Jagsonpal Pharmaceuticals Ltd

All Jagsonpal Pharmaceuticals Ltd announcements